severe cardiovascular disease
Conditions
Interventions
Synbiotic supplementation (Synprotec, Yakult Honsha Co., Ltd.) will be administered three times a day via a nasogastric tube. The intervention will be continued during the patient'
s stay in the cardiac care unit, for up to a maximum of 10 days
Sponsors
Hyogo Prefectural Amagasaki General Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients with acute severe cardiac disease who required ventilator management and were admitted to our hospital's CCU and who were started on enteral nutrition via a nasogastric tube
Exclusion criteria
Exclusion criteria: Pregnant or nursing patients Patients with medical conditions that preclude enteral nutrition (e.g., intestinal obstruction, gastrointestinal perforation) Patients who have been continuously using synbiotic supplementation prior to the start of the study Patients with a history of allergies to synbiotic supplementation Patients (or their legal representatives) decline to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of diarrhea (more than three watery stools per day), constipation (no bowel movements for more than three days), or infectious complications (respiratory-associated pneumonia, bacteremia, urinary tract infection, pseudomembranous enterocolitis) within 30 days after enrollment | — |
Countries
Japan
Contacts
Public ContactHiroyuki Nakayama
Hyogo Prefectural Amagasaki General Medical Center Department of Cardiology
Outcome results
None listed